Elicio Therapeutics (ELTX) Amortizatization of Intangibles (2024 - 2026)
Elicio Therapeutics' (ELTX) quarterly Amortizatization of Intangibles came in at $68000.0 in Q1 2026, up 94.29% YoY from $35000.0 in Q1 2025, and down 62.64% on a QoQ basis from $182000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 3 years of Amortizatization of Intangibles data on file, last reported at $68000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 94.29% year-over-year to $68000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $650000.0 (up 490.91% YoY) and the FY2025 annual result came in at $217000.0, up 189.33% from the prior year.
- Amortizatization of Intangibles retreated to $68000.0 in Q1 2026, from $182000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $400000.0 in Q3 2025 to a low of $26000.0 in Q3 2024.
- A 3-year average of $126666.7 and a median of $58500.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2025 — Amortizatization of Intangibles soared 1438.46% — and 2026, when it soared 94.29%.
- Tracing ELTX's Amortizatization of Intangibles over 3 years: stood at $49000.0 in 2024, then surged by 271.43% to $182000.0 in 2025, then sank by 62.64% to $68000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $68000.0 (Q1 2026), $182000.0 (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Jun 30, 2026 | 100,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 182,000.00 |
| Dec 31, 2025 | 182,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | 26,000.00 |
| Sep 30, 2024 | 26,000.00 |